These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 1972962)
1. Mitigation of obesity by BRL 26830A, a new beta-adrenoceptor agonist, in MSG obese mice. Yoshida T; Yoshioka K; Kamanaru K; Hiraoka N; Kondo M J Nutr Sci Vitaminol (Tokyo); 1990 Feb; 36(1):75-80. PubMed ID: 1972962 [TBL] [Abstract][Full Text] [Related]
2. Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice. Yoshida T; Hiraoka N; Yoshioka K; Hasegawa G; Kondo M Endocrinol Jpn; 1991 Aug; 38(4):397-403. PubMed ID: 1687027 [TBL] [Abstract][Full Text] [Related]
3. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents. Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555 [TBL] [Abstract][Full Text] [Related]
4. Substrate supply for thermogenesis induced by the beta-adrenoceptor agonist BRL 26830A. Wilson S; Thurlby PL; Arch JR Can J Physiol Pharmacol; 1987 Feb; 65(2):113-9. PubMed ID: 2882828 [TBL] [Abstract][Full Text] [Related]
5. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes. Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558 [TBL] [Abstract][Full Text] [Related]
6. The alpha/beta-adrenergic receptor blocker arotinolol activates the thermogenesis of brown adipose tissue in monosodium-L-glutamate-induced obese mice. Yoshida T; Sakane N; Wakabayashi Y; Yoshioka K; Umekawa T; Kondo M Int J Obes Relat Metab Disord; 1994 May; 18(5):339-43. PubMed ID: 7520314 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise. Santti E; Huupponen R; Rouru J; Hänninen V; Pesonen U; Jhanwar-Uniyal M; Koulu M Br J Pharmacol; 1994 Dec; 113(4):1231-6. PubMed ID: 7889277 [TBL] [Abstract][Full Text] [Related]
8. Effects of a beta 3-adrenoceptor agonist, BRL 26830A, on insulin and glucagon release in mice. Yoshida T; Hiraoka N; Kondo M Endocrinol Jpn; 1991 Dec; 38(6):641-6. PubMed ID: 1688048 [TBL] [Abstract][Full Text] [Related]
9. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Arch JR; Ainsworth AT Am J Clin Nutr; 1983 Oct; 38(4):549-58. PubMed ID: 6137948 [TBL] [Abstract][Full Text] [Related]
10. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist. Connacher AA; Jung RT; Mitchell PE Br Med J (Clin Res Ed); 1988 Apr; 296(6631):1217-20. PubMed ID: 2898268 [TBL] [Abstract][Full Text] [Related]
11. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice. Bryson JM; Wensley VR; Phuyal JL; Caterson ID; Cooney GJ Horm Metab Res; 1999 May; 31(5):317-22. PubMed ID: 10422727 [TBL] [Abstract][Full Text] [Related]
12. Effect of nicotine on norepinephrine turnover and thermogenesis in brown adipose tissue and metabolic rate in MSG obese mice. Yoshida T; Yoshioka K; Hiraoka N; Kondo M J Nutr Sci Vitaminol (Tokyo); 1990 Apr; 36(2):123-30. PubMed ID: 2388096 [TBL] [Abstract][Full Text] [Related]
13. Acute effects of a beta-adrenoceptor agonist (BRL 26830A) on rat brown-adipose-tissue mitochondria. Increased GDP binding and GDP-sensitive proton conductance without changes in the concentration of uncoupling protein. Milner RE; Wilson S; Arch JR; Trayhurn P Biochem J; 1988 Feb; 249(3):759-63. PubMed ID: 2895635 [TBL] [Abstract][Full Text] [Related]
15. Reduced brown adipose tissue thermogenesis and metabolic rate in pre-obese mice treated with monosodium-L-glutamate. Yoshioka K; Yoshida T; Kondo M Endocrinol Jpn; 1991 Feb; 38(1):75-9. PubMed ID: 1915115 [TBL] [Abstract][Full Text] [Related]
16. Clinical studies with the beta-adrenoceptor agonist BRL 26830A. Connacher AA; Bennet WM; Jung RT Am J Clin Nutr; 1992 Jan; 55(1 Suppl):258S-261S. PubMed ID: 1345890 [TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A. Connacher AA; Bennet WM; Jung RT; Rennie MJ Int J Obes Relat Metab Disord; 1992 Sep; 16(9):685-94. PubMed ID: 1356939 [TBL] [Abstract][Full Text] [Related]
18. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Yoshida T Am J Clin Nutr; 1992 Jan; 55(1 Suppl):237S-241S. PubMed ID: 1345886 [TBL] [Abstract][Full Text] [Related]
19. Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Wilson S; Arch JR; Thurlby PL Life Sci; 1984 Sep; 35(12):1301-9. PubMed ID: 6482654 [TBL] [Abstract][Full Text] [Related]
20. The effects of a new beta-adrenoceptor agonist BRL 26830A in refractory obesity. Chapman BJ; Farquahar DL; Galloway SM; Simpson GK; Munro JF Int J Obes; 1988; 12(2):119-23. PubMed ID: 2898457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]